Prediction of Overall Survival or Progression Free Survival by Disease Control Rate at Week 8 Is Independent of Ethnicity: Western Versus Chinese Patients With First-Line Non-Small Cell Lung Cancer Treated With Chemotherapy With or Without Bevacizumab

Categorizations of best response observed at week 8 of first-line treatment in two studies of bevacizumab plus chemotherapy in Western and Chinese patients with non-small cell lung cancer were assessed together with baseline prognostic factors in multivariate parametric models to predict overall survival and progression free survival.

Read More
Learn More